click enter text
under-model billion dollar
reiniti coverag octob highlight
gardasil underappreci growth driver convers
investor downstream launch weve learn radar
remain report describ gardasil opportun ahead part
dilig spoke mike nalli presid merck global vaccin
old vaccin midst major inflect point four
factor drive renew growth roll-out new geographi
develop develop china major contributor sinc age
expans product label age rang span y/o
depend geographi gender neutral recommend select
health agenc mean vaccin girl boy recommend
prevent spread hpv chang messag product
increas awar vaccin prevent sever differ type
cancer link hpv infect cervic cancer
biggest challeng face keep surg demand
scrambl maxim yield exist facil recent ear-
mark billion dollar new product sens wave new
demand could take come line howev
gener risk vaccin race patent clock
term competit approv product gsk cervarix
inferior offer less viru strain coverag help fill void
cant suppli market mean upsid gsk
hand emerg market compani hpv vaccin
develop noth develop market awar
think consensu could underestim gardasil
rais gardasil forecast result analysi
gardasil ep estim ahead consensu
fastest grow compani coverag ep growth near-term
reach doubl digit percent azn
addit detail us/eu drug compani cover see
re-initi oct global pharmaceut full length industri
trade fundament data
upsid target
factset/wolf research price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tabl content
impact
page
gardasil human papillomaviru hpv prevent vaccin market year
consist two differ product gardasil gardasil collect grown multi-billion-
dollar blockbust franchis exhibit seem destin eventu surpass prevnar becom
world biggest vaccin alreadi gardasil plu mrk third largest franchis keytruda
januvia/janumet ridicul sound gardasil could potenti rival keytruda term size
model
page
recent quarter grown increasingli vocal describ gardasil signific futur growth
driver compani exhibit investor often look past call
recent launch part stori under-appreci driver meaning addit
exhibit excerpt mrk ep confer call
exhibit addit recent mention gardasil
realli see unpreced increas world-wide
demand hpv vaccin doubl last year alon
term demand lot increas driven polici chang
gavi countri mani countri move demonstr
program multi-ag cohort
rob said realli work hard increas global
suppli hpv vaccin top prioriti us plan
significantli increas global suppli base look
next three year think demand go realli
continu grow go need suppli
would say peopl realli begin understand
import vaccin men women approv
cohort countri launch demand
continu grow nine year market see growth
see realli unpreced believ growth
continu strong
opportun gardasil global outsid us
there opportun new geographi china exemplar
uptak china continu strong new data
that introduc countri like australia realli lot
talk elimin campaign market around world
believ opportun gardasil short term long term
growth remain signific
 adam schechter mrk ep confer call
increas global suppli hpv vaccin top prioriti
merck plan place tripl global suppli
base next sever year even addit capac
merck abl meet unplan program
initi abl meet full demand china
near-monopoli hpv prevent vaccin market exhibit gsk cervarix
cover type approv product current around global market share
term revenu first approv product struggl cover two hpv
viru strain gsk withdrew cervarix us market due lack commerci traction leav
liter monopoli gsk also stop ship product certain market well
australia
page
exhibit hpv prevent vaccin ww market share product sale
develop program gardasil one gradual expans start primarili
vaccin girl young women prevent cervic cancer evolv vaccin appropri
broader age rang male prevent variou cancer beyond cervic
definit link hpv infect fda approv histori gardasil follow
june gardasil type first approv femal y/o prevent cervic
acip recommend routin vaccin girl y/o
june gardasil indic expans includ vulvar vagin cancer prevent
oct gardasil indic expans male y/o prevent genit wart
dec gardasil indic expans females/mal y/o prevent anal cancer
dec gardasil prior viru type approv femal y/o
indic male y/o smaller age rang indic
page
dec gardasil indic expans includ male y/o
oct gardasil dosag regimen chang goe seri seri
oct gardasil indic expans broader age rang females/mal
hpv strain type thought account cervic cancer type
thought account genit wart origin strain cover gardasil gardasil add five
addit strain top gardasil addit strain estim bring cervic cancer protect
level improv protect hpv-relat cancer rang
hpv infect increasingli recogn risk factor sever differ cancer gain broader
embrac public health agenc regulatori bodi around globe hpv common
sexual transmit infect american adult age core risk-factor host variou
cancer limit cervic cancer major differ hpv strain typic resolv
strain lead cancer hpv infect frequent root caus behind cervic
anal vagin cancer hpv account greatest absolut number case within
oropharyng cancer subset within head neck cancer exhibit show hpv link cancer us
center diseas control prevent cdc wolf research
given increas bodi evid around impact effect hpv immun cancer incid
mortal issu polici statement urg aggress effort increas hpv vaccin
link earlier year came offici call-to-act help end suffer caus cervic
cancer highlight import role hpv vaccin link us acip recommend girl
page
cancer typeavg us case per year case like caus hpv case like caus
boy age get vaccin intern recommend countri introduc nation hpv
point australia clearest evid gardasil real-world valu proposit australia
wildli success hpv immun program garner signific media attent countri claim
march toward erad cervic cancer altogeth link new york time guardian one
first countri adopt nation immun program gardasil approv program start
australia seen hpv infect rate women age drop
pre-gardasil post-gardasil free hpv vaccin program introduc australia school
system first girl age extend boy femal
male age date three hpv vaccin dose sourc hpvregist org au
actual evid lower cervic cancer incid take time bear develop cervic
cancer often present decad hpv infect drop incid rate expect becom
appar initi cohort y/o vaccin femal reach age rang closer
year old research model countri annual cervic cancer incid rate drop six case
per women fewer four case per women australia annual
incid rate could less one case per women exhibit detail model
assumpt see underli lancet public
exhibit forecast annual incid cervic cancer australia
vaccin rate outsid australia includ us often much lower could gap close
vaccin rate vari substanti countri even develop world public health initi
implement roll countri level australia uk spain sweden south africa
rate around averag us canada germani closer rwanda first
low-incom countri provid free access hpv vaccin support gavi achiev stun
page
rate girl year old franc low lowest japan less
due vaccin scare regard neurolog find singl mous gain widespread media attent
cultur dynam also impact countri rate adopt even well-fund nation immun
program exist gardasil initi sometim describ std prevent vaccin young girl
critic claim may promot promiscu among young adult
exhibit summar inform report detail qualiti recenc vari wide countri
exhibit hpv vaccin immun rate countri
medic literatur vaccin coverag rate receiv least dose wolf research
given chang messag gardasil incorpor contemporari find show link
hpv sever differ cancer low adopt countri becom high adopt countri difficult
predict seem happen
may unit nations-memb countri introduc nation hpv
hic america denot paho pan american health organ vastli outpac middl
incom countri mic low-incom countri denot gavi private-publ global health allianc
vaccin poorer countri
page
exhibit hpv introduct statu countri
adapt wolf research
hic led initi wave hpv nation immun program adopt exhibit non-gavi mic fallen
crack bit dont healthcar budget hic unfortun sit
gni/capita threshold requir gain access gavi support non-gavi mic voic concern around
afford implement hpv nation immun program
page
exhibit publicli fund hpv nation vaccin program countri year
gardasil price vari greatli depend countri exhibit
collect vaccin acquisit price countri remov individu countri name gener
aggreg file variou metric obtain hpv vaccin price around world
clean data includ recent price either analysi file
trace back either gardasil end total discret countri estim
price/dos usd segment calcul straight averag constitu countri match
descript characterist
page
exhibit gardasil price/dos region incom level gavi statu valenc
high end price rang us explicitli disclos file
educ guess back-test report sale inform cdc
compar us list price low end gavi countri buy product
organ negoti price averag price/dos across countri
sampl distribut non-norm exhibit posit skew percentil
respect
page
china market alon multibillion-dollar opportun consensu mis-model
china account world incid case cervic cancer april china food
drug administr cfda condit approv gardasil approv revamp cfda came
eight day mrk older quadrival version gardasil approv may
lengthi review process gsk bival cervarix first hpv vaccin approv china juli
peopl women new case cervic cancer annual chines market
prime roll-out effect hpv prevent vaccin
despit import cancer-prev product gardasil paid out-of-pocket china
gardasil categori vaccin china mean provinci reimburs
patient must pay out-of-pocket access vaccin categori vaccin fulli reimburs gener
sell much lower price point vast major made local chines manufactur gardasil
get upgrad categori vaccin anytim soon
demand china hpv prevent vaccin explod despit need pay out-of-pocket
hard imagin nalli press articl bbg fiercepharma report chines women travel thousand
mile line hour clinic door receiv hpv vaccin local demand strong
current suppli inadequ gardasil shortag even led mass protest outsid mrk hong
kong offic june link what go chines women race get hpv vaccin
two main reason one hand medic tourism grow trend among china wealthi
travel hong kong gardasil avail sinc receiv latest hpv vaccin
dose becom somewhat common rout almost creat statu symbol within china say
nalli gardasil view like luxuri good hand real-world data support
use anti-canc vaccin novel consum engag strategi wildli success rais
hpv awar gsk first leverag alibaba ali health platform link allow user
access educ inform cervic cancer find healthcar provid follow suit march
link estim theyr reach women target fashion platform
alon addit nalli mention wechat messag china premier acknowledg hpv
intens market demand vaccin fuel consum engag nalli estim
scratch surfac china volum could go futur
sell gardasil local chines distributor chongq zhifei biolog product
ink origin deal zhifei follow approv gardasil merck disclosur
sale product individu market apart us fortun case gardasil
chines distributor refut accuraci specif
zhifei disclos sept claim would purchas worth gardasil
link
howev updated/increas approv gardasil april zhifei latest
disclosur plan purchas worth gardasil
link consider step-up previou contract exhibit
page
exhibit mrk contract zhifei new vs old
figur base suppli price zhifei reflect record revenu
book suppli gardasil gardasil price charg
end-us zhifei hold respons determin local market price allow captur spread
say zhifei one bear demand side risk simpli supplier case press articl
report patient spend anywher singl dose gardasil includ
mark-up within distribut channel accur expens us us list price
gardasil gavi price data base massiv price premium
presum fuel limit suppli chines market commit quadrupl suppli
gardasil china fear still might enough satisfi demand ft report demand shanghai
current outstrip suppli link
gsk also talk china opportun like remain small player gsk often
afterthought within context global hpv vaccin market gsk get china first gsk manag
also start talk cervarix growth opportun china although quit consist
vigor exhibit
exhibit excerpt recent broker confer jun
invest quit bit behind vaccin busi great busi china weve got cervarix
approv well
cervarix strongli launch china
cervarix gardasil cervarix bival gardasil quadrival nonaval
approv china label also differ
age rang cervarix approv y/o femal broader gardasil y/o
major cervarix usag younger adolesc popul wherea gardasil traction
older adult popul usag trend may evolv clear chines
trial underway tri close age gap gardasil cervarix howev even never achiev
age expans gardasil still superior product broader strain coverag cash pay
market consum may particularli sensit idea gardasil better product contrast
gsk decid go alon china commerci cervarix rather partner
term competit beyond gsk merck acknowledg compani local asian market
work version hpv vaccin chines korean indian manufactur current
page
variou stage clinic trial version bival quadrival hpv vaccin
nonaval global time report five chines firm current phase develop shanghai
zerun one contend link nation institut diagnost vaccin
develop infecti diseas nidvd base xiamen univers current phase develop
bival hpv vaccin candid nidvd vaccin expect launch link even make
market would like compet local unclear whether would view trust
product unclear volum product compani could produc furthermor least
today viru strain coverag less competit threat could greater gsk
chines hpv target market almost unfathom larg estim chines women
fall within elig gardasil cohort abil pay vaccin attempt size market
use back-of-the-envelop math address target popul penetr rate
price suppli gardasil gardasil market today skew
toward gardasil given gardasil recent launch estim heavili skew
toward gardasil time given cash pay market gardasil provid better protect
assum product mix steadi state level mean averag suppli price
weight averag gardasil better product
complianc gardasil approv regimen china unlik us
regimen assum assum complianc rate mean averag women get
recommend shot would seem like point china could also switch
regimen assumpt averag shot receiv would still
market share quadrival nonaval vaccin domin global market
better virtu higher hpv strain coverag gsk still captur sale
launch first base mrk zhifei contract detail gsk report cervarix sale ytd
estim gsk current split china market today roughli respect sake
exercis assum market share shift
exhibit take assumpt account toggl size address target popul size
mrk penetr rate within share overal hpv pie show mrk potenti gardasil sale
china million usd use mrk estim size elig femal cohort women
penetr market size china alon would nearli importantli assum
penetr gardasil male popul
page
note sensit tabl assum averag suppli price averag b/t gardasil complianc rate market share
gardasil still much front end commerci roll-out china best tell potenti
chines women receiv vaccin date nalli estim million women
consensu model chines opportun appropri admittedli recent
also under-estim impact say estim like rise take mid-point current
annual china run rate assumpt assum collect
zhifei per contract current consensu estim dont make sens next two year impli
ex-u ex-china market begin deterior unlik scenario given china market
see sudden surg growth driven increas recognit gardasil benefit coupl
broaden label exhibit
exhibit consensu ex-u gardasil forecast dont account china correctli
